Does the media refer more to CTMX or PHVS?

In the previous week, Pharvaris had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for CytomX Therapeutics. Pharvaris' average media sentiment score of 0.63 beat CytomX Therapeutics' score of 0.10 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLS or CTMX?

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than CytomX Therapeutics. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 3 mentions for CytomX Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.21 beat CytomX Therapeutics' score of 0.10 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTMX or NKTR?

In the previous week, Nektar Therapeutics had 21 more articles in the media than CytomX Therapeutics. MarketBeat recorded 24 mentions for Nektar Therapeutics and 3 mentions for CytomX Therapeutics. Nektar Therapeutics' average media sentiment score of 0.18 beat CytomX Therapeutics' score of 0.10 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor AUPH or CTMX?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 3 mentions for CytomX Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 0.69 beat CytomX Therapeutics' score of 0.10 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTMX or BCRX?

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 3 articles in the media. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat CytomX Therapeutics' score of 0.10 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CytomX Therapeutics (CTMX) Competitors

$2.56 -0.07 (-2.66%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.60 +0.04 (+1.37%)

As of 10/2/2026 07:30 PM Eastern

Compare

CTMX vs. PHVS, SLS, NKTR, AUPH, and BCRX

Should you buy CytomX Therapeutics stock or one of its competitors? CytomX Therapeutics's main competitors and comparable companies include Pharvaris (PHVS), SELLAS Life Sciences Group (SLS), Nektar Therapeutics (NKTR), Aurinia Pharmaceuticals (AUPH), and BioCryst Pharmaceuticals (BCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CytomX Therapeutics compare to Pharvaris?

CytomX Therapeutics (NASDAQ:CTMX) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Pharvaris has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Pharvaris	N/A	-61.40%	-56.00%

CytomX Therapeutics currently has a consensus target price of $11.90, indicating a potential upside of 364.84%. Pharvaris has a consensus target price of $59.87, indicating a potential upside of 91.94%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Pharvaris had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for CytomX Therapeutics. Pharvaris' average media sentiment score of 0.63 beat CytomX Therapeutics' score of 0.10 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 11.8% of Pharvaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CytomX Therapeutics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, suggesting that its stock price is 346% less volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Summary

CytomX Therapeutics beats Pharvaris on 11 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

SELLAS Life Sciences Group has a beta of 2.56, indicating that its stock price is 156% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 14.82%. CytomX Therapeutics has a consensus target price of $11.90, indicating a potential upside of 364.84%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than CytomX Therapeutics. MarketBeat recorded 8 mentions for SELLAS Life Sciences Group and 3 mentions for CytomX Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.21 beat CytomX Therapeutics' score of 0.10 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

SELLAS Life Sciences Group has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. SELLAS Life Sciences Group's return on equity of -35.91% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

CytomX Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Nektar Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

In the previous week, Nektar Therapeutics had 21 more articles in the media than CytomX Therapeutics. MarketBeat recorded 24 mentions for Nektar Therapeutics and 3 mentions for CytomX Therapeutics. Nektar Therapeutics' average media sentiment score of 0.18 beat CytomX Therapeutics' score of 0.10 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nektar Therapeutics has a net margin of -287.84% compared to CytomX Therapeutics' net margin of -435.21%. Nektar Therapeutics' return on equity of -37.87% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Nektar Therapeutics	-287.84%	-37.87%	-25.67%

CytomX Therapeutics currently has a consensus target price of $11.90, suggesting a potential upside of 364.84%. Nektar Therapeutics has a consensus target price of $138.50, suggesting a potential upside of 217.81%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Nektar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

CytomX Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A
Nektar Therapeutics	$55.23M	26.94	-$164.08M	-$6.70	N/A

Summary

CytomX Therapeutics beats Nektar Therapeutics on 8 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and CytomX Therapeutics (NASDAQ:CTMX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Aurinia Pharmaceuticals has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.44	$287.20M	$2.29	6.91
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A

Aurinia Pharmaceuticals has a net margin of 100.84% compared to CytomX Therapeutics' net margin of -435.21%. Aurinia Pharmaceuticals' return on equity of 26.11% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Aurinia Pharmaceuticals currently has a consensus price target of $17.67, suggesting a potential upside of 11.60%. CytomX Therapeutics has a consensus price target of $11.90, suggesting a potential upside of 364.84%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 3 mentions for CytomX Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 0.69 beat CytomX Therapeutics' score of 0.10 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aurinia Pharmaceuticals beats CytomX Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to BioCryst Pharmaceuticals?

CytomX Therapeutics (NASDAQ:CTMX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, CytomX Therapeutics and CytomX Therapeutics both had 3 articles in the media. BioCryst Pharmaceuticals' average media sentiment score of 0.31 beat CytomX Therapeutics' score of 0.10 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has higher revenue and earnings than CytomX Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A
BioCryst Pharmaceuticals	$874.84M	2.39	$263.86M	-$1.50	N/A

CytomX Therapeutics presently has a consensus price target of $11.90, suggesting a potential upside of 364.84%. BioCryst Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 150.92%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

CytomX Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to CytomX Therapeutics' net margin of -435.21%. CytomX Therapeutics' return on equity of -38.46% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Summary

CytomX Therapeutics beats BioCryst Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$573.07M	$3.87B	$7.14B	$13.18B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-5.12	13.06	274.83	26.04
Price / Sales	30.48	1,297.71	616.61	84.99
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	4.41	16.63	10.93	6.31
Net Income	-$17.37M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-5.19%	-2.98%	-2.00%	-1.66%
1 Month Performance	-30.43%	-10.59%	-6.15%	-4.50%
1 Year Performance	-22.42%	19.46%	7.45%	2.06%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	1.9679 of 5 stars	$2.56 -2.7%	$11.90 +364.8%	-22.0%	$573.07M	$18.30M	N/A	69
PHVS Pharvaris	4.2584 of 5 stars	$36.02 -1.0%	$59.87 +66.2%	+34.6%	$2.38B	N/A	N/A	148
SLS SELLAS Life Sciences Group	0.5233 of 5 stars	$11.37 -1.0%	$10.00 -12.0%	+586.5%	$2.32B	N/A	N/A	13
NKTR Nektar Therapeutics	3.4818 of 5 stars	$66.84 -0.4%	$141.50 +111.7%	-28.0%	$2.29B	$55.23M	N/A	63	Trending News Analyst Forecast
AUPH Aurinia Pharmaceuticals	3.6355 of 5 stars	$16.61 -1.7%	$17.67 +6.4%	+40.6%	$2.25B	$283.05M	7.25	128

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. PHVS, SLS, NKTR, AUPH, and BCRX

How does CytomX Therapeutics compare to Pharvaris?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does CytomX Therapeutics compare to Nektar Therapeutics?

Summary

How does CytomX Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does CytomX Therapeutics compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. PHVS, SLS, NKTR, AUPH, and BCRX

How does CytomX Therapeutics compare to Pharvaris?

Is CTMX or PHVS more profitable?

Do analysts recommend CTMX or PHVS?

Does the media refer more to CTMX or PHVS?

Do insiders & institutionals believe in CTMX or PHVS?

Which has more risk & volatility, CTMX or PHVS?

Which has stronger earnings & valuation, CTMX or PHVS?

Summary

How does CytomX Therapeutics compare to SELLAS Life Sciences Group?

Which has more volatility & risk, SLS or CTMX?

Do analysts recommend SLS or CTMX?

Do insiders and institutionals believe in SLS or CTMX?

Which has preferable earnings & valuation, SLS or CTMX?

Does the media favor SLS or CTMX?

Is SLS or CTMX more profitable?

Summary

How does CytomX Therapeutics compare to Nektar Therapeutics?

Do institutionals and insiders have more ownership in CTMX or NKTR?

Which has more volatility and risk, CTMX or NKTR?

Does the media refer more to CTMX or NKTR?

Is CTMX or NKTR more profitable?

Do analysts rate CTMX or NKTR?

Which has stronger valuation & earnings, CTMX or NKTR?

Summary

How does CytomX Therapeutics compare to Aurinia Pharmaceuticals?

Which has better valuation & earnings, AUPH or CTMX?

Is AUPH or CTMX more profitable?

Do analysts rate AUPH or CTMX?

Do insiders and institutionals hold more shares of AUPH or CTMX?

Which has more risk and volatility, AUPH or CTMX?

Does the media favor AUPH or CTMX?

Summary

How does CytomX Therapeutics compare to BioCryst Pharmaceuticals?

Do institutionals and insiders have more ownership in CTMX or BCRX?

Does the media favor CTMX or BCRX?

Which has stronger earnings & valuation, CTMX or BCRX?

Do analysts prefer CTMX or BCRX?

Which has more risk & volatility, CTMX or BCRX?

Is CTMX or BCRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools